Specific targeting of cancer vaccines to antigen-presenting cells via an endogenous TLR2/6 ligand derived from cysteinyl-tRNA synthetase 1

Hyeong Yun Kim,Seongmin Cho,Sang Bum Kim,Ee Chan Song,Wonchul Jung,Yun Gyeong Shin,Ji Hun Suh,Jihye Choi,Ina Yoon,Uijoo Kim,Hamin Ban,Sunkyo Hwang,Jeongwon Mun,Joohee Park,Nayoung Kim,Youngjin Lee,Myung Hee Kim,Sunghoon Kim
DOI: https://doi.org/10.1016/j.ymthe.2024.07.014
2024-07-25
Abstract:Cancer vaccines have been developed as a promising way to boost cancer immunity. However, their clinical potency is often limited due to the imprecise delivery of tumor antigens. To overcome this problem, we conjugated an endogenous Toll-like receptor (TLR)2/6 ligand, UNE-C1, to human papilloma virus type 16 (HPV-16)-derived peptide antigen, E7, and found that the UNE-C1-conjugated cancer vaccine (UCV) showed significantly enhanced antitumor activity in vivo compared with the noncovalent combination of UNE-C1 and E7. The combination of UCV with PD-1 blockades further augmented its therapeutic efficacy. Specifically, the conjugation of UNE-C1 to E7 enhanced its retention in inguinal draining lymph nodes, the specific delivery to dendritic cells and E7 antigen-specific T cell responses, and antitumor efficacy in vivo compared with the noncovalent combination of the two peptides. These findings suggest the potential of UNE-C1 derived from human cysteinyl-tRNA synthetase 1 as a unique vehicle for the specific delivery of cancer antigens to antigen-presenting cells via TLR2/6 for the improvement of cancer vaccines.
What problem does this paper attempt to address?